We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

RADIOFREQUENCY ABLATION DEVICES MARKET FOR PAIN MANAGEMENT ANALYSIS

Radiofrequency Ablation Devices Market For Pain Management, By Product [Equipment, Reusables (Probes, Electrodes), Disposables (Cannulas, Needles, RF-Single Use Probe, RF- Single Use Electrodes)], By Application (Cardiology, Oncology, Gynecology, Pain Management, and Others), By End User (Hospitals, Ambulatory Surgical Centers, and Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : Nov 2023
  • Code : CMI4252
  • Pages :176
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Market News

Global Radiofrequency Ablation Devices Market For Pain Management: Key Developments

On June 28, 2023, Japan Lifeline Co., Ltd., a medical device company, entered into an exclusive distribution agreement with Haemonetics Japan GK, a healthcare company, for

VASCADE MVPTM, a vascular closure device for femoral veins used after ablation surgery for atrial fibrillation.

On June 27, 2023, NeuroOne Medical Technologies, a company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary Radio Frequency (RF) generator

On June 19, 2023, Avanos Medical, Inc., a medical device company, announced it has entered into a definitive agreement to acquire Diros Technology Inc., a leading manufacturer of innovative Radio Frequency (RF) products used to treat chronic pain conditions.

On April 7, 2023, Compal Electronics, a leading electronics company, announced the launch of a new radiofrequency ablation (RFA) system for percutaneous, intraoperative coagulation and ablation of soft tissue, including partial or complete ablation of non-resectable liver lesions and a Bilevel ventilator for chronic obstructive pulmonary disease and respiratory insufficiency caused by central and/or mixed apneas.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.